DBV Technologies | DBVT - Passività Correnti





Passività Correnti Cambiamento Data
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amarin USD 179.64M 14.82M 2026-03
BioCryst Pharmaceuticals USD 196.07M 5.83M 2025-12
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
DBV Technologies USD 58.02M 8.54M 2025-12
Esperion Therapeutics USD 300.81M 58.22M 2025-12
Galectin Therapeutics USD 14.62M 1.98M 2024-06
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Incyte USD 1.49B 25.52M 2026-03
Insmed USD 468.87M 51.66M 2025-12
Ionis Pharmaceuticals USD 717M 66M 2026-03
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
PTC Therapeutics USD 968.43M 102.18M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
United Therapeutics USD 599.1M 38.5M 2026-03